← Back to Search

Device

iRF System Hepatic Denervation for Type 2 Diabetes (DeLIVER Trial)

N/A
Waitlist Available
Research Sponsored by Metavention
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30, 90, 180 and 365 days
Awards & highlights

DeLIVER Trial Summary

This trial is testing a new device to see if it safely improves glycemic control in type 2 diabetes patients.

DeLIVER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30, 90, 180 and 365 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30, 90, 180 and 365 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of Serious Adverse Device Effects
Secondary outcome measures
Adverse Event rate 365 days
Change in glycemic control - C-peptide
Change in glycemic control - FPG
+4 more

DeLIVER Trial Design

1Treatment groups
Experimental Treatment
Group I: Hepatic DenervationExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
iRF System Hepatic Denervation
2020
N/A
~20

Find a Location

Who is running the clinical trial?

MetaventionLead Sponsor
3 Previous Clinical Trials
121 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
California
How old are they?
65+
What site did they apply to?
Stanford University Medical Center
What portion of applicants met pre-screening criteria?
Met criteria
~3 spots leftby Apr 2025